Harvard School of Public Health
Peter Neumann
Institute for Clinical Research and Health Policy Studies
Tufts Medical Center
Peter J. Neumann, Sc.D., is Director of the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. Prior to joining Tufts, he was on the faculty of the Harvard School of Public Health for ten years, most recently as Associate Professor of Policy and Decision Sciences. His research focuses on the use of cost-effectiveness analysis in health care decision making. He has conducted numerous economic evaluations of medical technologies, including evaluations of treatments for Alzheimer’s disease. He is the founder and director of the Cost-Effectiveness Registry (www.cearegistry.org), a comprehensive database of cost-effectiveness analyses in health care. Dr. Neumann has contributed to the literature on the use of willingness to pay and quality-adjusted life years (QALYs) in valuing health benefits. His other research has focused on the Food and Drug Administration's regulation of health economic information, and the role of clinical and economic evidence in informing public and private sector health care decisions, including those made by the Medicare program. He is the author or co-author of over 150 papers in the medical literature, and the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005). He is a member of the editorial boards of Health Affairs and Value in Health. Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and as a trustee of the Society for Medical Decision Making. He has also held several policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. He received his doctorate in health policy and management from the Harvard University.
We assessed how much, if anything, people would pay for a laboratory test that predicted their future disease status. A questionnaire was administered via an internet-based survey to a random sample of adult US respondents. Each respondent answ... (more »)
In June 2009, the Federal Coordinating Council for Comparative Effectiveness Research submitted a report to the President and Congress in which the Council described the purpose of comparative effectiveness research (CER) as developing evidence... (more »)
We assessed how much, if anything, people would pay for a laboratory test that predicted their future disease status. A questionnaire was administered via an internet-based survey to a random sample of adult US respondents. Each respondent answ... (more »)